The short version of human growth hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-29 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
=== Reunited Germany, 1990–present === East Germany had originally consisted of five states (i.e., Brandenburg, Mecklenburg-Vorpommern, Saxony, Saxony-Anhalt, and Thuringia). In 1952, these states were abolished and the East was divided into 14 administrative districts called Bezirke. Soviet-controlled East Berlin – despite officially having the same status as West Berlin – was declared East Germany's capital and its 15th district. The debate on territorial revision restarted shortly before German reunification. While academics (Rutz and others) and politicians (Gobrecht) suggested introducing only two, three, or four states in East Germany, legislation reconstituted the East German states in an arrangement similar to that which they had had before 1952, as the five "New States" on 3 October 1990. The former district of East Berlin joined West Berlin to form the new state of Berlin. Henceforth, the 10 "old states", plus 5 "new states", plus the new state of Berlin, add up to the current 16 states of Germany. After reunification, the constitution was amended to state that the citizens of the 16 states had successfully achieved the unity of Germany in free self-determination and that the West German constitution thus applied to the entire German people. Article 23, which had allowed "any other parts of Germany" to join, was rephrased. It had been used in 1957 to reintegrate the Saar Protectorate as the Saarland into the Federal Republic, and this was used as a model for German reunification in 1990.
Industry, constituting 19.74% of GDP and 24% of total employment, is the second-largest sector. Large-scale manufacturing (LSM) dominates, representing 12.2% of GDP, with cement production thriving due to demand from Afghanistan and the domestic real estate sector. In 2013, Pakistan exported 7,708,557 metric tons of cement, with an installed capacity of 44,768,250 metric tons. The textile industry, a key player in Pakistan's manufacturing, contributes 9.5% to GDP and employs around 15 million people. As of 2022, Pakistan ranks seventh globally in cotton production, with substantial spinning capacity, making it a major exporter of textile products in Asia. China has been a significant buyer of Pakistani textiles, importing US$1.527 billion worth of textiles in 2012.
=== Mechanism of action === It is a selective inhibitor of the enzyme janus kinase 1 (JAK1). It inhibits JAK1 by 28 fold of selectivity over JAK2 and more than 340 fold of selectivity over JAK3. Two mechanisms are involved in atopic dermatitis, one involves epidermal barrier disruptions, and the other one is cutaneous inflammation due to the immune system over response. Acute inflammation in AD typically involves IL-13, IL-4, and IL-33. Consequently, inhibiting JAK1 results in suppressing the signaling cytokines IL-4, IL-3, and IL-31. Many other cytokines are involved in AD and mediated by JAK1 such as type II cytokine receptors for IL-22, IL-19, IL-10, IL-20 and glycoprotein 130 (gp130) including IL-6 and IL-12 which are also associated with JAK2 and TYK2; IFN-α and INF-β signal.
=== Detection of aircraft === In 1931, Arnold Frederic Wilkins joined Watt's staff in Slough. As the "new boy", he was given a variety of menial tasks to complete. One of these was to select a new shortwave receiver for ionospheric studies, a task he undertook with great seriousness. After reading everything available on several units, he selected a model from the General Post Office (GPO) that worked at (for that time) very high frequencies. As part of their tests of this system, in June 1932 the GPO published a report, No. 232 Interference by Aeroplanes. The report recounted the GPO testing team's observation that aircraft flying near the receiver caused the signal to change in intensity, an annoying effect known as fading. The stage was now set for the development of radar in the UK. Using Wilkins' knowledge that shortwave signals bounced off aircraft, a BBC transmitter to light up the sky as in Appleton's experiment, and Watt's RDF technique to measure angles, a complete radar could be built. While such a system could determine the angle to a target, it could not determine its range and provide a location in space. To do so, two such measurements would have to be made from different locations. Watt's huff-duff technique solved the problem of making rapid measurements, but the issue of coordinating the measurement at two stations remained, as did any inaccuracies in measurement or differences in calibration between the two stations.
== Advantages == Intermediate moisture foods utilize hurdle technology by lowering water activity, reducing pH and using preservatives. Most bacteria do not grow under a water activity of 0.90 and IMF processing methods reduce water activity to 0.60-0.84. IMFs are often ready-to-eat and do not require refrigeration. This is especially important in countries with tropical climates and minimal storage and processing capacities. Nitrites and sulfites are added to food to prolong shelf life and delay flavor and color changes. Propylene glycol reduces water activity and acts as a plasticizing agent to give food its desired texture. Compared to canning, dehydration, and freezing, IMF food processing is less rigorous and results in less nutrient loss. This is because compared to other processing techniques, IMF processes are at lower temperatures, pressures, and there is no water leaching of nutrients. Additionally, IMF production is more energy efficient compared to conventional processes including canning and freezing since IMFs do not require refrigeration. The energy required for canning and freezing is costly, thus IMF are common in developing countries.
Sources: en.wikipedia.org
===== MeSH D08.811.277.151 – aminohydrolases ===== MeSH D08.811.277.151.300 – gtp cyclohydrolase MeSH D08.811.277.151.350 – guanine deaminase MeSH D08.811.277.151.418 – methenyltetrahydrofolate cyclohydrolase MeSH D08.811.277.151.486 – nucleoside deaminases MeSH D08.811.277.151.486.075 – adenosine deaminase MeSH D08.811.277.151.486.250 – cytidine deaminase MeSH D08.811.277.151.486.625 – cytosine deaminase MeSH D08.811.277.151.653 – nucleotide deaminases MeSH D08.811.277.151.653.060 – amp deaminase MeSH D08.811.277.151.653.200 – dcmp deaminase
Because of this fact, it has become common practice to establish the quality of NMR ensembles, by comparing it against the unique conformation determined by X-ray diffraction, for the same protein. However, the X-ray diffraction structure may not exist, and, since the proteins in solution are flexible molecules, a protein represented by a single structure may lead to underestimate the intrinsic variation of the atomic positions of a protein. A set of conformations, determined by NMR or X-ray crystallography may be a better representation of the experimental data of a protein than a unique conformation. The utility of a model will be given, at least in part, by the degree of accuracy and precision of the model. An accurate model with relatively poor precision could be useful to study the evolutionary relationships between the structures of a set of proteins, whereas the rational drug design requires both precise and accurate models. A model that is not accurate, regardless of the degree of precision with which it was obtained will not be very useful. Since protein structures are experimental models that can contain errors, it is very important to be able to detect these errors. The process aimed at the detection of errors is known as validation. There are several methods to validate structures, some are statistical like PROCHECK and WHAT IF while others are based on physical principles as CheShift, or a mixture of statistical and physics principles PSVS.
Susan M Gaines is an American writer. She is the author of the novels Accidentals (2020) and Carbon Dreams (2001), and co-author with Geoffrey Eglinton and Jurgen Rullkötter of the science book Echoes of Life: What Fossil Molecules Reveal about Earth History (2009). Her short stories have been nominated twice for the Pushcart Prize. She is a former fellow of the Hanse Institute for Advanced Study in Germany. In 2018, she was awarded a Suffrage Science Award for women in science and science writers who have inspired others.
Professor Richard Hilary Templer. Lately Director of Innovation, Grantham Institute, Imperial College London. For services to Climate Innovation. Dr. Gillian Romaine Tett. Editorial Board, Financial Times. For services to Economic Journalism. Usha Ladwa-Thomas. Race Adviser, Welsh Government. For services to Black, Asian and Minority Ethnic Communities. Margaret Ann Throup, MP. Member of Parliament for Erewash. For Political and Public Service. Jane Elizabeth Toogood. Co-Chair, Hydrogen Delivery Council. For services to the Low Carbon Hydrogen Sector. Sara Louise Tough. Executive Director, Children's Services, Norfolk County Council. For services to Education and Children's Social Care. John Henry Trayner. Lately Managing Director, Go-Ahead London. For services to Transport, to Skills and to Education in London. Marcus Edward Trescothick. Mental Health Ambassador, Professional Cricketers' Association. For services to Mental Ill Health. Professor Joyce Ann Tyldesley. Professor of Egyptology, University of Manchester. For services to Egyptology and Heritage. Nicola Madeline van der Drift. Chief Executive, International Bomber Command Centre. For services to Heritage. Louise van der Straeten. Senior Lawyer, Serious Fraud Office. For services to the Administration of Justice. Vinaichandra Guduguntla Venkatesham. Chief Executive Officer, Arsenal Football Club. For services to Sport. Ewan Andrew Venters. Chief Executive, Hauser & Wirth and Chair, GREAT Private Sector Council. For services to International Trade. Robert Iain Wainwright. Founder, Doddie Aid.
=== In Europe === Recently, EFLM has chosen the name of "Specialists in Laboratory Medicine" to define all European Clinical pathologists, regardless of their training (M.D., Ph.D. or Pharm.D.). In France, Clinical Pathology is called Medical Biology ("Biologie médicale") and is practiced by both M.D.s and Pharm.D.s. The residency lasts four years. Specialists in this discipline are called "Biologiste médical" which literally translates as Clinical Biologist rather than "Clinical pathologist".
Sources: en.wikipedia.org
The other common method for introducing the Fmoc group is through 9-fluorenylmethylsuccinimidyl carbonate (Fmoc-OSu), which may itself be obtained by the reaction of Fmoc-Cl with the dicyclohexylammonium salt of N-hydroxysuccinimide. Reacting with 9-fluorenylmethyloxycarbonyl azide (itself made by reacting Fmoc-Cl with sodium azide) in sodium bicarbonate and aqueous dioxane is also a method to install Fmoc group. Because the fluorenyl group is highly fluorescent, certain UV-inactive compounds may be reacted to give the Fmoc derivatives, suitable for analysis by reversed phase HPLC. Analytical uses of Fmoc-Cl that do not use chromatography may be limited by the requirement that excess Fmoc-Cl be removed before an analysis of fluorescence.
In 2024, Dalman and colleagues described the remains of a tyrannosaur discovered in 1983 in the Campanian-early Maastrichtian Hall Lake Formation in New Mexico. Reposited at the New Mexico Museum of Natural History and Science, the fossil material (NMMNH P-3698) consists of the right postorbital, right squamosal, left palatine, and an incomplete maxilla from the skull, the left dentary, right splenial, right prearticular, right angular and right articular from the lower jaws, isolated teeth, and chevrons. Some of the bones were briefly mentioned in 1984 as belonging to T. rex, and described in 1986. Lehman and Carpenter (1990) suggested that NMMNH P-3698 belonged to a new tyrannosaurid genus, while Carr and Williamson (2000) disagreed with their claim. Sullivan and Lucas (2015) argued that there is little evidence to support NMMNH P-3698 as a specimen of Tyrannosaurus rex, so they tentatively classified it as cf. Tyrannosaurus sp.; they also considered that the McRae tyrannosaur lived before the Lancian (before 67 million years ago) based on its probable association with the Alamosaurus fossil.
=== Proliferative phase === In the proliferative phase, immature granulation tissue containing plump, active fibroblasts forms. Fibroblasts quickly produce abundant type III collagen, which fills the defect left by an open wound. Granulation tissue moves, as a wave, from the border of the injury towards the center. As granulation tissue matures, the fibroblasts produce less collagen and become more spindly in appearance. They begin to produce the much stronger type I collagen. Some of the fibroblasts mature into myofibroblasts which contain the same type of actin found in smooth muscle, which enables them to contract and reduce the size of the wound.
== Decay properties == The detailed decay mechanism to form the stable daughter nuclide tellurium-125 is a multi-step process that begins with electron capture, which produces a tellurium-125 nucleus in an excited state with a half-life of 1.6 ns. The excited tellurium-125 nucleus may undergo gamma decay, emitting a gamma photon at 35.5 keV, or undergo internal conversion to emit an electron. The electron vacancy from internal conversion results in a cascade of electron relaxation as the core electron hole moves toward the valence orbitals. The cascade involves many characteristic X-rays and Auger transitions. In the case the excited tellurium-125 nucleus undergoes gamma decay, a different electron relaxation cascade follows before the nuclide comes to rest. Throughout the entire process an average of 13.3 electrons are emitted (10.3 of which are Auger electrons), most with energies less than 400 eV (79% of yield). The internal conversion and Auger electrons from the radioisotope have been found in one study to do little cellular damage, unless the radionuclide is directly incorporated chemically into cellular DNA, which is not the case for present radiopharmaceuticals which use 125I as the radioactive label nuclide. Rather, cellular damage results from the gamma and characteristic X-ray photons. As with other radioisotopes of iodine, accidental iodine-125 uptake in the body (mostly by the thyroid gland) can be blocked by the prompt administration of stable iodine-127 in the form of an iodide salt. Potassium iodide (KI) is typically used for this purpose.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.